Arc Institute
Eli Lilly and Genetic Leap partner to develop RNA-targeted therapies in deal worth $409m
The companies will use Genetic Leap's AI platform to generate oligonucleotide drugs against targets selected by Lilly
Vertex and Orum partner on gene editing conditioning drugs in deal worth $945m
The agreement gives Vertex the rights to use Orum’s targeted protein degradation technology
Scientists discover new form of gene editing to recombine and rearrange DNA
The bridge RNA system allows researchers to edit, delete and convert DNA recombinases without using CRISPR
Regeneron and Mammoth announce gene editing partnership worth $370m per target
The companies will aim to develop CRISPR-based therapies for multiple tissues and cell types
Amgen takes aim at cardio diseases with Arrowhead RNAi deal
Licenses two gene silencing programmes with up to $670m in the offing for the specialist
Janssen partners with Isis on stomach conditions
Will develop treatments that target RNA in people with autoimmune disorders
Silence Therapeutics appoints Michael Khan as chief medical adviser
Will advise on translational research for its siRNA-based therapeutics